PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
136 hedge funds and large institutions have $278M invested in PDL BioPharma, Inc. in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 45 reducing their positions, and 15 closing their positions.
227% more call options, than puts
Call options by funds: $245K | Put options by funds: $75K
33% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 15
7% more capital invested
Capital invested by funds: $260M → $278M (+$18.7M)
3% more funds holding
Funds holding: 132 → 136 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
20% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$8.91M |
| 2 |
Goldman Sachs
New York
|
+$3.88M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$2.4M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.38M |
| 5 |
CCM
Context Capital Management
Lajolla,
California
|
+$2.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$2.42M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.18M |
| 3 |
Charles Schwab
San Francisco,
California
|
-$1.91M |
| 4 |
ECM
Engine Capital Management
New York
|
-$1.53M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.35M |
PDLI Hedge Fund Activity: Q2 2020 in Review
136 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q2 2020, worth a combined $278M — up 7.2% from $260M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PDLI positions and 15 closed out — a net gain of 5 holders — while 36 added to existing stakes and 45 trimmed.
The largest buyer was State Street, adding an estimated $8.91M. The largest seller was Connor, Clark & Lunn Investment Management (CC&L), cutting an estimated $2.42M.
- 136 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q2 2020, up from 132 in Q1 2020.
- Funds reported $278M of PDL BioPharma, Inc. stock for Q2 2020, up 7.2% quarter-over-quarter.
- 20 funds opened new PDL BioPharma, Inc. positions in Q2 2020 and 15 closed out, a net change of +5 holders.
- The largest PDL BioPharma, Inc. buyer in Q2 2020 was State Street, an estimated $8.91M added.
- The largest PDL BioPharma, Inc. seller in Q2 2020 was Connor, Clark & Lunn Investment Management (CC&L), an estimated $2.42M sold.
Based on aggregated 13F filings for Q2 2020.